The engine that keeps people on GLP-1 treatment.
We tell the prescriber which patients are about to drop off, before they sign the next refill.
See the engine work.
A look at the weekly check on the patient's phone, and what reaches the prescriber at the refill.
More than half of patients stop a GLP-1 within the first year, before they have had the benefit.
53.6% discontinue within 12 months. JAMA Network Open, 2025.
What it does before each refill.
It sits on top of the clinic's own system and writes nothing back.
It reads the orders the clinic already holds, and a weekly check from the patient's phone.
At the refill it surfaces the patient with the evidence, and drafts the message a clinician would send.
The clinician decides. Nothing about the dose is automated.
Screens are illustrative, with synthetic patients.
A provider that bills monthly loses the subscription as soon as a patient stops. Payers and employers have paid for a drug the patient is no longer taking, and pharma loses sight of the patient once the drug is dispensed.
Shaped by the clinics closest to the problem.
We develop this with clinics and prescribers, around the way they already handle a refill.